Clik here to view.
Aquinox sitting pretty ahead of Phase 2a data
With a strong investor syndicate of venture capital funds, closely held Aquinox Pharmaceuticals of Vancouver is in an enviable position ahead of the release, in June, of Phase 2a clinical trial results...
View ArticleClik here to view.
Brainsway reports positive smoking cessation results
Brainsway (TASE:BRIN) has reported additional positive final results in a clinical trial at Israel’s Be’er Ya’akov Mental Health Center to assess the efficacy of its Deep TMS device in inducing smoking...
View ArticleClik here to view.
Leerink starts Bellerophon Therapeutics at outperform
Leerink Partners has launched coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with an “outperform” rating and $19 price target. The stock closed at $9.75 on Friday. Bellerophon is focused on the...
View ArticleClik here to view.
Inogen POCs represent paradigm shift in oxygen therapy
Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...
View ArticleClik here to view.
MediciNova to release asthma and COPD trial results in Q2
MediciNova (NASDAQ:MNOV; OSE:4875) expects to release results from two clinical trials in the current second quarter with its lead drug candidate, MN-221, opening the door to a possible pivotal trial....
View ArticleClik here to view.
Piper Jaffray starts Inogen at neutral
Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday. “We truly appreciate the unique technology the...
View ArticleClik here to view.
Leerink starts Theravance Biopharma at outperform
Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin...
View Article